Oncotarget is a peer-reviewed medical journal that is published on a weekly basis. Oncotarget was established in 2010 by its editors-in-chief Dr. Mikhail Blagosklonny and Dr. Andrei V. Gudkov. For most of the time that Oncotarget has been published is has focused on research in the field of Oncology. The medical journal recently added new sections for additional fields of medicine beyond Oncology including among others Neuroscience, Cardiology, Metabolism, Endocrinology, and Pharmacology. Oncotarget is also available on Dove Press.
Oncotarget, which is provided with free-access, mission is to make the results of research broadly available. It also seeks to break down the wall between different medical specialties and encourage the clinical research in order to fight diseases. Among recent research that was published in Oncotarget is a paper written by Irfan Rahman, Ph.D., who works at the Ur School of Medicine and Dentistry as a Professor of Environmental Medicine. His research study that was published in Oncotarget shows that it is likely that electronic cigarettes are just as damaging to gums and teeth as conventional cigarettes are. Another recent research article published in Oncotarget showed that early stage Alzheimer’s can be seen in a profile of 6 blood borne MicroRNA.
Both Dr. Mikhail Blagosklonny and Dr. Andrei V. Gudkov work at the Roswell Park Cancer Institute in Buffalo, New York. The editorial board of Oncotarget is made up of medical professionals around the world including among other those from Stanford University, Temple University, Harvard Medical School, John Hopkins University, the Unversity of Rome, and INSERM in Paris, France.
Dr. Blagosklonny is a Professor of Oncology and also a researcher. His research is focused on cancer and anti-aging. He is a well-known advocate of using the cancer drug Rapamycin as a possible candidate for extending people’s lives. Dr. Gudkov is also a well-known cancer researcher who specializes in drug discovery, gene discovery, and molecular targets in the treatment of cancer. Follow Oncotarget journal on Twitter.